An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas
- 17 March 2021
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 479 (3) , 481-491
Abstract
Primary gastrointestinal neuroendocrine carcinoma (GI-NEC) cannot be distinguished morphologically from pulmonary neuroendocrine carcinoma (P-NEC). This can present a significant diagnostic challenge in cases where site of origin cannot be readily determined. To identify immunohistochemical (IHC) markers that can be used to reliably distinguish between GI-NECs and P-NECs, we constructed 3-mm tissue microarrays, one containing 13 GI-NECs and one containing 20 P-NECs. IHC was performed on both microarrays using 21 stains: AE1/AE3, CK7, CK20, synaptophysin, chromogranin, CD56, INSM1, SSTR2A, CDX2, SATB2, TTF1, Napsin A, PR, GATA3, PAX8, ISL1, beta-catenin, AFP, SMAD4, Rb, and p53. For GI-NEC, the most strongly expressed marker was synaptophysin (mean H-score 248), while AE1/AE3 was the most strongly expressed in P-NEC (mean H-score 230), which was stronger than in GI-NEC (p = 0.011). Other markers that were stronger overall in P-NEC than in GI-NEC included CK7 (p < 0.0001) and TTF1 (p < 0.0001). Markers that were stronger overall in GI-NEC than in P-NEC included SSTR2A (p = 0.0021), SATB2 (p = 0.018), CDX2 (p = 0.019), and beta-catenin (nuclear; p = 0.029). SMAD4, Rb, and p53 showed similar rates of abnormal protein expression. Based on these results, a stepwise algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A had a 91% overall accuracy in distinguishing these GI-NEC from P-NEC. This was tested on a second cohort of 10 metastatic GI-NEC and 10 metastatic P-NEC, with an accuracy in this cohort of 85% and an overall accuracy of 89% for the 53 cases tested. Our algorithm reasonably discriminates GI-NEC from P-NEC using currently available IHC stains.Keywords
This publication has 57 references indexed in Scilit:
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal CancersGastroenterology, 2012
- SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal CarcinomasAmerican Journal of Surgical Pathology, 2011
- TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodiesVirchows Archiv, 2010
- An Immunohistochemical Study of Cervical Neuroendocrine Carcinomas: Neoplasms That are Commonly TTF1 Positive and Which May Express CK20 and P63American Journal of Surgical Pathology, 2010
- Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ casesAnnals of Oncology, 2009
- THE FORMATION OF STREPTOLYSIN O UNDER STABILIZED pH CONDITIONSActa Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology, 2009
- Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysisLaboratory Investigation, 2006
- Small Cell Lung Carcinoma (SCLC)American Journal of Surgical Pathology, 2002
- Tumor doubling time and prognostic assessment of patients with primary lung cancerCancer, 1994